Orange Biomed (CEOs Woong-Hyeon Koh and Yeseul Park), which develops a microfluidic-based glycated hemoglobin (A1C) measuring medical device, announced that it was selected as one of the 'Fortune Korea's Top 40 Emerging S. Korean Healthcare Innovations' by Fortune Korea, a global economic magazine.
This selection was based on evaluations by leading US healthcare experts (Key Opinion Leaders) and the global consulting firm BDMT Global. Comprehensive evaluations were conducted on a variety of criteria, including innovation, market fit, and potential for US market entry. Companies with technologies that address unmet needs in the US healthcare landscape received particularly high marks.
The panel of judges evaluated that “Orange Biomed’s small device based on microfluidic technology, ‘OBM rapid A1c,’ has the potential to solve the accessibility problem of existing laboratory-based glycated hemoglobin tests.”
Orange Biomed possesses the world's first microfluidic-based physical method for measuring glycated hemoglobin, and is currently developing a miniaturized diagnostic device utilizing this technology. This technology is expected to contribute to improving blood sugar management and monitoring accessibility for diabetes patients.
Meanwhile, the company is currently running the 'MAP YOUR HEALTH' campaign to prevent chronic diseases, and is also working to increase its awareness in the North American market, such as by recently holding a local event in Chicago in collaboration with more than 18 health and community organizations.
Orange Biomed Co-CEO Park Ye-seul said, “This selection is a recognition of Orange Biomed’s technological prowess and growth potential in the global healthcare sector,” and added, “We will expand our networking and business opportunities for entry into the U.S. market and achieve tangible results.”
- See more related articles
You must be logged in to post a comment.